NCT06724653

Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Chungnam National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.

Detailed description

Patients described above randomly assigned to drug tapering group and drug maintaining group. Drug tapering group is 2 groups, which one is RAS blocker tapering group and others is beta blocker tapering group. Drug tapering group is monitored ejection fraction, LV dimension and LV GLS by 1-3 month.

Conditions

• Heart Failure
• Ejection Fraction
• Recovery of Function

Interventions

Type	Name	Description
DRUG	RAS blocker tapering group	RAS blocker tapering out
DRUG	Beta blocker tapering out	Beta blocker tapering out group

Timeline

• Start date: 2025-03-06
• Primary completion: 2025-05-26
• Completion: 2027-11-26
• First posted: 2024-12-09
• Last updated: 2026-03-27

Locations

2 sites across 1 country: South Korea